Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Related Keywords

San Diego ,California ,United States ,Cherise Adkins ,Steve Hughes ,Kathleen Gallagher ,Mike Maclean ,Eli Lilly ,Sarah Boyce ,Linkedin ,Twitter ,Company Contact ,Prnewswire Avidity Biosciences Inc ,Nasdaq ,Exchange Commission ,Development Rd Expenses ,Clinical Trial Research Network ,European Medicines Agency ,Avidity Biosciences Inc ,Antibody Oligonucleotide Conjugates ,Duchenne Muscular Dystrophy ,Trial Research Network ,Motor Outcomes ,Validate Evaluations Plus ,Cash Equivalents ,Marketable Securities ,Oligonucleotide Conjugates ,Private Securities Litigation Reform Act ,Avidity Biosciences ,Nc ,